Board meeting set to approve September quarter results

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹14.23

prior close

₹14.49

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.2%-2.1% vs sector

On the reaction day the stock moved 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-10.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3pendingpending-0.2-2.1

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the quarter ended September 30, 2026, this notice provides no consolidated figures and no comparison with the quarter ended September 30, 2025. The board will meet on November 12, 2026 at 3:00 PM to approve unaudited standalone results. Trading by designated persons remains closed until November 14, 2026.

Likely market impact

No earnings figures are disclosed, so the notice gives no clear direction for the stock. Trading by designated persons stays closed until November 14, 2026.

By the numbers

The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.